Saniona's collaboration partner initiates preclinical development in joint ataxia programme.
M2 EQUITYBITES-August 15, 2017-Saniona's collaboration partner initiates preclinical development in joint ataxia programme
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Biotechnology company Saniona AB (STO:SANION) announced on Monday that Luc Therapeutics, its collaboration partner and a private biotechnology company, has initiated preclinical development for the drug candidate CAD-1883 for ataxia.
The company said Luc Therapeutics has initiated the pre-clinical development with the aim of initiating Phase 1 first man clinical studies in 2018.
Also, Luc Therapeutics will be responsible for further development of compounds identified under the Ataxia programme.
Apart from being a shareholder of Luc Therapeutics, Saniona has rights to royalties on products commercialised by Luc Therapeutics under the Ataxia programme.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 15, 2017|
|Previous Article:||Sweco commissioned for SEK300m project to plan and design modernisation of Stockholm Central Station.|
|Next Article:||Autoliv announces dividend of USD0.60 per share for quarter.|